Ranbaxy's indinavir capsules prequalified by WHO
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories' antiretroviral, indinavir sulfate 400mg capsules, has been prequalified by the World Health Organization (WHO). Ranbaxy now has 19 ARVs on the WHO pre-qualification list. The company has been providing ARV medicines at affordable prices in more than 70 markets worldwide since 2001 and its products are now used by more than 400,000 patients in various developing and underdeveloped countries.